Nanobiotix (ENXTPA:NANO) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NANO 주식 개요

임상 단계의 생명공학 회사인 나노바이오틱스는 암 치료 및 기타 미충족 의료 수요를 충족하기 위한 제품 후보 개발에 주력하고 있습니다.

NANO 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	1/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 92% 에서 거래

수익은 연간 8.62% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

마이너스 주주 지분

최근 3개월간 주가 변동폭 심해

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

Nanobiotix S.A. 경쟁사

MaaT Pharma

ENXTPA:MAAT

€99.5m

Inventiva

ENXTPA:IVA

€145.8m

Sensorion

ENXTPA:ALSEN

€214.4m

Aelis Farma

ENXTPA:AELIS

€168.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Nanobiotix
과거 주가
현재 주가	€4.45
52주 최고치	€10.40
52주 최저치	€3.82
베타	1.23
11개월 변경	-31.43%
3개월 변경 사항	-21.93%
1년 변경 사항	-4.09%
33년 변화	-62.51%
5년 변화	-55.41%
IPO 이후 변화	-28.23%

최근 뉴스 및 업데이트

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 29

Recent updates

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 29

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

May 14

주주 수익률

	NANO	FR Biotechs	FR 마켓
7D	12.3%	-4.7%	-2.2%
1Y	-4.1%	-29.3%	-3.1%

수익률 대 산업: NANO 지난 1년 동안 -30 %를 반환한 French Biotechs 산업을 초과했습니다.

수익률 대 시장: NANO 지난 1년 동안 -3.1 %를 반환한 French 시장과 일치했습니다.

가격 변동성

Is NANO's price volatile compared to industry and market?
NANO volatility
NANO Average Weekly Movement	10.3%
Biotechs Industry Average Movement	7.1%
Market Average Movement	4.7%
10% most volatile stocks in FR Market	9.2%
10% least volatile stocks in FR Market	2.6%

안정적인 주가: NANO 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: NANO 의 주간 변동성( 8% )은 지난 1년 동안 안정적이었지만 여전히 French 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2003	102	Laurent Levy	www.nanobiotix.com

임상 단계의 생명공학 기업인 나노바이오틱스는 암 치료 및 기타 미충족 의료 수요를 위한 제품 후보를 개발하는 데 주력하고 있습니다. 주요 제품 후보로는 연조직 육종, 두경부암, 간암, 전립선암, 췌장암, 식도암, 직장암, 비소세포폐암 치료에 사용되는 결정질 하프늄 산화물 나노입자의 멸균 수성 현탁액인 NBTXR3가 있습니다. 이 회사는 리안 온콜로지 리미티드와 파트너십을 맺고 중화권, 한국, 싱가포르, 태국에서 NBTXR3를 개발 및 상용화하고 있습니다.

Nanobiotix S.A. 기본 사항 요약

Nanobiotix 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NANO 기본 통계
시가총액	€209.64m
수익(TTM)	-€39.70m
수익(TTM)	€36.21m

5.8x

P/S 비율

-5.3x

P/E 비율

NANO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NANO 손익 계산서(TTM)
수익	€36.21m
수익 비용	€0
총 이익	€36.21m
기타 비용	€75.91m
수익	-€39.70m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.84
총 마진	100.00%
순이익 마진	-109.64%
부채/자본 비율	-2,467.9%

NANO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NANO 주식 개요

보상

위험 분석

Nanobiotix S.A. 경쟁사

ENXTPA:MAAT

€99.5m

ENXTPA:IVA

€145.8m

ENXTPA:ALSEN

€214.4m

ENXTPA:AELIS

€168.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Recent updates

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

Price target increased by 15% to €25.17

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Price target decreased to €21.90

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Price target decreased to €22.90

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Price target decreased to €23.18

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Price target increased to €29.67

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Consensus EPS estimates fall to -€1.29